SNMMI 2017: Personalized PRRT Improves Radiation Delivery to Neuroendocrine Tumors

Key Points

  • Ordinarily, patients receive a fixed amount of radioactivity in several sequential cycles. This marks the first time that 177Lu-octreotate PRRT has been matched to the patient's individual tolerance based on SPECT dosimetry.
  • Results showed an increase in the radiation dose to tumors for a majority of participants—increases as high as three times the dose delivered with conventional PRRT.
  • Serious side effects and toxicity remained infrequent with the personalized approach. 

Neuroendocrine tumors are difficult to manage and unlikely to be cured, but researchers intend to slow progression of these tumors and aid survival by personalizing patient doses of peptide receptor radionuclide therapy (PRRT), according to research presented at the 2017 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) (Abstract 242).

Peptide Receptor Radionuclide Therapy

PRRT has become a treatment of choice for neuroendocrine tumors. The targeted treatment is designed to hone in on and attach to peptide receptor–positive tumors, while sparing tissues that might otherwise be damaged by systemic treatments. However, researchers are still perfecting the practice.  

“So far, the majority of PRRT treatments have been administered one-size-fits-all, meaning every patient receives about the same amount of radioactivity,” said Jean-Mathieu Beauregard, MD, Assistant Professor in the Department of Radiology and Nuclear Medicine at Université Laval in Quebec City, Canada. “This results in highly variable absorbed radiation doses to organs and tumors. Many patients may not draw the maximum benefits from PRRT because they end up receiving a lesser dose than their body can realistically tolerate.”

Study Details

For this study, researchers used a PRRT called lutetium-177 (177Lu)-octreotate, which mimics the somatostatin growth-inhibiting hormone. Ordinarily, patients receive a fixed amount of radioactivity, such as 200 mCi, in several sequential cycles. This marks the first time that 177Lu-octreotate PRRT has been matched to the patient's individual tolerance based on single-photon emission computed tomography (SPECT) dosimetry, which evaluates how much radiation is building up in key organs, like the kidneys.

A total of 27 patients with neuroendocrine tumors underwent 55 personalized 177Lu-octreotate cycles from April to December 2016, followed by quantitative SPECT dosimetry. Radiation dose was quantified for the kidneys to optimize the administered amount of radioactivity, while remaining safe and well-tolerated by patients. Side effects were recorded and blood counts, as well as renal and hepatic biochemistry, were performed at 2, 4, and 6 weeks after each cycle of treatment.

Major Results

Results showed an increase in the radiation dose to tumors for a majority of participants—increases as high as three times the dose delivered with conventional PRRT. Furthermore, serious side effects and toxicity remained infrequent with the personalized approach. 

Additional research is planned for the coming months to determine how personalized PRRT results in improved therapeutic benefits, such as reduced tumor progression and longer survival.

The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.


Advertisement

Advertisement



Advertisement